BillionToOne
Menlo Park
About BillionToOne
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $425.9M
- Funding stage: IPO
- Last round: Series D (Jun 2024)
- Ticker: nasdaq:BLLN
- Website: billiontoone.com
- Phone: +1 650-460-2551
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/billiontoone-3155 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.